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Nutrition treatment does not improve  
the efficacy of oncological treatment
Aleksandra Kapała
A beneficial effect of nutrition treatment on multiple aspects of oncological therapy is chiefly demonstrated by pre-
venting and in treating the wasting syndrome and cancer cachexia accompanying the cancer disease. The presence of 
the wasting syndrome prior to commencing treatment is associated with shorter time for developing complications 
along with a shorter overall survival (OS), worse response to oncological treatment, deteriorating quality of life, poorer 
general status; moreover, cachexia strongly affects treatment tolerance. Clinical nutrition is one of the most significant 
pillars supporting oncological treatment, nonetheless, one has to be mindful of certain cases where nutritional inte-
rvention, especially parenteral nutrition, does not bring benefits, and may even be harmful to the patient. Such cases 
include: PN (parenteral nutrition) for patients with normal body mass and a correctly functioning gastrointestinal tract; 
PN due to hypoalbuminemia, in patients where feeding via the gastrointestinal tract is possible (orally or enterally); 
lack of refeeding syndrome prevention for cachectic patients starting PN or EN; use of feeding mixtures containing 
only soya oil as the sole fatty nutrient; incomplete nutrition (macronutrients or micronutrients only); inclusion of PN 
in patients in the terminal phase of cancer undergoing persistent nutrition therapy.
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Introduction 
The protocol for conducting clinical nutrition with pa-
tients suffering from cancer is detailed in the EU guidelines 
of 2016 [1], as well as in the Polish guidelines of 2015 [2]. 
A beneficial effect of nutrition treatment on multiple aspects 
of oncological therapy is shown mainly by preventing and 
treating the wasting syndrome and cancer cachexia accom-
panying the tumour disease. The presence of the wasting 
syndrome prior to commencing treatment is associated with 
a shorter time to developing complications, with shorter 
overall survival (OS), worse response to oncological treat-
ment, deteriorating quality of life, poorer general fitness; 
moreover, cachexia strongly affects treatment tolerance [3–9]. 
The status of clinical nutrition as a fully eligible method of 
aiding treatment in clinical oncology is now undisputable. 
Nutritional intervention may reduce surgical complications 
and the healing rates of wounds and mucosal reactions; it 
reduces infection rates and also treatment toxicity, it improves 
patients’ general fitness and life quality, shortens hospitali-
sation time and diminishes treatment costs [10]. Nutritional 
preparation often helps a patient to start oncological therapy 
in the first place, or facilitates its continuation.
However, despite the indisputable benefits of clinical 
nutrition for oncological patients, there are cases where 
nutrition intervention not only fails to improve a patient’s 
general condition, but may even worsen it. This article is 
devoted to situations in oncology where one should refrain 
from feeding; it also pinpoints frequent practical errors likely 
to entail serious consequences. 
Applying parenteral nutrition to non-cachectic 
patients with a correctly functioning 
gastrointestinal tract, i.e. for whom PN  
should not be used
Parenteral nutrition has been used since the 70s of 
the last century. Initially, the success achieved with this 
309
treatment method for patients undergoing surgical treat-
ment and cachectic patients have led to the attempts in 
using parenteral nutrition for cancer patients to prevent 
radiotherapy complications; especially post-radiation in-
flammation of the mucous membranes [10]. Efforts were 
also made to administer parenteral nutrition to patients 
with a correct body mass and a correctly functioning ga-
strointestinal tract undergoing oncological treatment, in 
order to decrease treatment toxicity and enhance treatment 
outcomes. 109 randomised studies and 4,000 patients were 
analysed in a literature review by Koretz et al. [11] which 
did not demonstrate any advantages in using parenteral 
nutrition. The potential harm, of increased infection rates 
in those undergoing PN, was however noticed. There was 
no beneficial effect on treating the complications arising 
from radio- and chemotherapy whenever PN was used. 
Current ESPEN guidelines underline that a nutritional in-
tervention should be carried out in the first place through 
the gastrointestinal tract (orally, intragastrically by tube or 
gastrostomy, or enterally — by tube or jejunostomy). When 
neither of these methods can be used, and if the gastrointe-
stinal tract cannot be accessed, (e.g. due to an obstruction), 
only then can nutritional intervention be applied via the 
intravenous route (the peripheral or central route). This 
recommendation is substantiated by an understanding of 
the pathophysiological changes occurring in the gastro-
intestinal tract if feeding is via the intravenous route. The 
basic phenomena include:
 — Atrophy of villi, decreased blood flow rate in villi, lower 
hormone secretion of the gastrointestinal tract and ab-
sorption of nutrients;
 — Damage to the natural protective barrier: smaller pro-
duction of mucus and IgA;
 — Changes to the intestinal flora, bacterial translocation 
and increasing permeability of the mucosal barrier;
 — Lower secretion of digestive juices;
 — Slowed peristalsis;
 — Damaged liver, steatohepatitis, incorrect rotation of 
bile salts acids;
 — Adverse changes in the function of lymphocytes B and T, 
macrophages and in the efficiency of chemotaxis and 
phagocytosis.
Considering the above, the ESPEN recommends if po-
ssible, to combine parenteral and enteral feeding. It is tho-
ught that even trophic feeding (minimum enteral feeding, 
delivering below 400 kcal per day) already has a beneficial 
effect on the pathophysiological changes described above. 
It is the most often requested clinical practice to ad-
minister PN for patients with hypoalbuminemia. However, 
even if a hypoalbuminemia patient is cachectic, but the 
gastrointestinal tract works efficiently and an oral or enteral 
intervention is possible, it is a mistake to administer PN for 
such a patient. Hypoalbuminemia in oncology is, first of 
all, a sign of a tumour disease’s activity, of cachexia and of 
the accompanying inflammation as well as a sign that the 
production of liver-produced proteins has been distorted to 
acute phase proteins. There are then no sufficient substrates 
for albumin production and concentrations of this protein 
fall dramatically. Unfortunately, PN will not compensate for 
this disorder. Effective causal oncological therapy will only 
improve this parameter. 
Prevention of the refeeding syndrome (RF),  
i.e. less is more
Another common situation in clinical practice is that 
appropriate prevention of the refeeding syndrome is lac-
king; a potentially fatal complication of not only parenteral, 
but also enteral feeding. A mortality rate for a developed 
RF reaches 50%. The RF is a syndrome of severe metabo-
lic disorders related to a critical deficiency of phosphates, 
potassium, magnesium and thiamine. The RF can also be 
referred to as a metabolic syndrome, because the shortage 
of phosphates prevents the activity of the ATPase, a pump 
necessary for producing energy for the transformation of 
macronutrients; mainly hydrocarbons. A consequence of 
the metabolic syndrome is metabolic acidosis, a shift in the 
haemoglobin dissociation curve to the left, cell lysis, and 
consequently, a rapidly evolving failure of all the systems 
and organs essential for living together with impaired con-
sciousness. Exposed to RF development are those patients 
subject to protracted starvation and cachectic patients, i.e. 
such as is often seen in cancer patients. If parenteral nutri-
tion is recommended for a cachectic patient, a calorie supply 
of < 50% of the calculated demand should always be started 
with, (usually 5–10 kcal/kg of the current body mass), and 
then built up gradually by increasing calories from 100 to 
250 every 3 days [13–17]. Additional doses of thiamine, pho-
sphates and vitamins dissolved in water are used in the first 
days of nutrition. Sometimes, in the first day, liquids and mi-
cronutrients are only given to balance out water-electrolyte 
abnormalities and PN is started on the second or third day. 
In case of enteral nutrition for extremely cachectic and long 
starving patients, a < 50% of the protein-energy demand 
is also begun with; isocaloric or peptide diets are willingly 
accepted, and some of the micronutrients are supplemented 
via the intravenous route. It should be kept in mind that 
the best RF treatment method is prevention. Practically, for 
a cachectic patient with the body weight of 40 kg, an initial 
supply of protein and energy should be between 200 and 
400 kcal and should gradually increase every 2–3 days to 
the target values depending on treatment tolerance. Most 
hospitals do not possess a nutrition laboratory, and only 
have ready-made 3-chamber bags with the calorific value 
substantially exceeding the above values. The number of 
calories supplied in such cases should be adjusted to the 
demand (a part of the bag to be applied).
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Selection of fatty nutrients, i.e. not only is 
protein important
Since the onset of adopting clinical nutrition, focus has 
been laid on proteins — as being the nutrient dictating 
the renewal of tissues and cells in a body under starvation. 
Regardless of the above, a fatty component is also important 
and the current ESPEN recommendations say that fats are to 
cover 50% of calories from non-protein energy in a cancer 
patient’s daily energy demand. The selection of a fatty com-
ponent is also essential [18]. The first fat used in parenteral 
nutrition was soya oil, rich in long chain fatty acids (LCT), 
including unsaturated fatty acids of the omega-6 group. In 
the light of modern knowledge it is known that omega-6 
acids interfere with the cyclooxygenase cycle and promote 
the production of proinflammatory and prothrombotic cy-
tokines such as series-2 prostanoids, series-2 thromboxan 
and series-4 leukotrienes. There are concerns that promotion 
of systemic inflammation may support an inflammatory 
micro-environment, which facilitates cancer cell growth. In 
particular this happens by increased production of hypoxia 
induced factors (HIF). The hypoxia environment strengthens 
angiogenesis on the other hand, and the formation of new 
blood vessels allows the tumour to obtain nutrients, oxygen, 
which conditions its growth, survival and, consequently, 
enables potential metastasis [19]. It was additionally shown 
that nutrition based on soya only extends the hospitalisation 
time by 1.6 day per each 100 g of soya oil [20]. For this reason, 
it is a mistake to use mixtures only containing soya oil. Bags 
are currently commercially available containing medium 
chain triglycerides (MCT), olive oil rich in group n-9 fatty 
acids and unsaturated fatty acids of the omega-3 group [20]. 
All the aforementioned fatty components are important for 
a patient suffering from cancer. Soya oil should not be used 
as the only fatty component, however, it cannot be totally 
eliminated. MCT-type acids are a unique component absor-
bed directly to the blood system and consumed by the liver 
as a source of energy. Unlike LCT, they do not require the 
digestion of lipases, and are not transported by lymphatic 
routes. They are more readily available as a source for energy 
production than LCT acids. It is important that MCT acids 
exhibit a protein saving effect. Beta-hydroxybutyrate acid 
and acetoacetic acid, being a fuel for mitochondria instead 
of glucoses, are produced from them. Hence, by substituting 
glucoses, they limit gluconeogenesis from the body’s own 
proteins [21]. All these MCT metabolic distinctions are espe-
cially vital for cachectic patients and allow for faster energy 
gain. Unsaturated fatty acids of the omega-3 group exhibit 
anti-inflammatory action, interfere with the cyclooxygenase 
cycle and promote the production of cytokines with a smal-
ler inflammatory potential, namely series-3 prostanoids, 
series-3 thromboxan and series-5 leukotrienes. As a fatty 
nutrient in parenteral and enteral feeding, they are recom-
mended for surgery patients irrespective of the body mass 
in case of surgery of the upper section of the gastrointestinal 
tract and head and neck, and also for malnourished patients 
intended for extensive abdominal cavity procedures. They 
are also recommended for the acute respiratory distress 
syndrome (ARDS), and for liver insufficiency. The last two 
cases may represent severe complications of oncological 
therapy. Nonetheless, olive oil containing neutral n-9 fatty 
acids has a neutral effect on the inflammatory process; it 
neither fuels it, as do omega-6 acids, nor diminishes it, as do 
omega-3 acids. In current clinical practice, bags containing 
LCT and olive oil are proposed for undernourished, non-
-surgery patients, especially in palliative care.
Incomplete nutrition, i.e. how to make one’s own 
action ineffective
One of the key parenteral nutrition principles in oncolo-
gy is the principle of nutrition completeness, meaning that 
a feeding mixture has to contain macronutrients: protein, 
hydrocarbons, fats, and also micronutrients: vitamins, mi-
nerals, trace elements [22]. Commercially produced feeding 
bags for parenteral nutrition however only contain macro-
nutrients. Micronutrients have to be added (by a syringe). 
Only then can the so prepared mixture be administered to 
the patient. From a physiological standpoint, a bag supply-
ing only macronutrients is ineffective; only when micronu-
trients are added, can hydrocarbons, protein and fats be 
effectively incorporated and transformed by the human 
body. Micronutrients are a component of many enzymes, 
hormones, carrier proteins and other substances which 
precondition the correct metabolism of macronutrients. 
Cases where any nutrient has to be excluded are rare and 
provisional, e.g. fats are excluded for treating chyle leak, 
vitamins A in liver insufficiency or copper and molybdenum 
in cases of cholestasis [23]. Complete nutrition mixtures are 
used routinely. An issue concerning settlements with the 
National Heath Fund (NFZ) may also be important. Lower 
valuations are made for incomplete feeding as compared 
to complete mixtures. 
Palliative medicine, i.e. the time  
of difficult decisions
Parenteral nutrition in palliative medicine still arouses 
many controversies, and the decisions made at this time 
of a patient’s life are the most difficult. In accordance with 
ESPEN guidelines, such support can be proposed to cachec-
tic patients where feeding via the gastrointestinal tract is 
not possible, the patient agrees to such a procedure, and 
the estimated survival time is more than 2 months. On the 
other hand, these recommendations clearly state that PN 
should not be used to patients at the terminal phase of 
their life, only small amounts of fluids are to be sufficient, 
administered by the oral or subcutaneous route, and that the 
use of intravenous infusion is justified only by impairments 
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to consciousness due to dehydration [24, 25]. The meaning 
of the term ‘palliative’ has largely changed in the recent 
years, as it indeed it denotes a condition where healing is 
not possible, and where life can only be extended and the 
disease symptoms reduced. Now however this phase may 
last several years even, as in contrast to the term ‘terminal’; 
meaning the last days, maybe weeks of life. For terminally 
ill patients, parenteral nutrition is contraindicated, and pro-
bably aggravates metabolic disorders and accelerates the 
patient’s demise. If a patient, who is being nourished, enters 
the terminal phase, parenteral nutrition should be disconti-
nued; in this situation, the patient no longer benefits from 
such a protocol [26]. For a patient in the palliative phase of 
treatment likely to survive at least 2 months, a decision to 
stop parenteral nutrition is difficult and is case-specific as 
always. Recommendations for PN usage do not differ from 
general recommendations. A malnourished patient, with 
good or average fitness (PS ≤ 2 or 3, improvable through 
symptomatic treatment), with a relatively stable dissemi-
nated malignant disease (without aggressive progression) 
and with relatively efficient organs, will benefit from such 
support. The last statement relates chiefly to the respiratory 
and blood circulation system, for instance patients with 
a massive exudation in pleural cavities, superior vena cava 
syndrome (SVCS) or massive metastases to lungs limiting 
respiratory capacity, or a patient with symptomatic heart 
failure, will not be candidates for parenteral nutrition. Hy-
perbilirubinemia with massive changes to the liver through 
metastases or through cancer spreading in the upper level of 
the abdominal cavity (pancreatic cancers, stomach cancers) 
poses a large problem; PN may strengthen cholestasis in this 
case. Nevertheless, the presence of kidney failure treated 
conservatively or with dialyses or the presence of diabetics 
in the insulin therapy phase, do not represent a major con-
straint in eligibility for PN if the above-mentioned problems 
are properly treated and tracked. 
Summary
Clinical nutrition is one of the most significant pillars 
supporting oncological treatment, however, one has to be 
mindful of the cases where nutritional intervention, espe-
cially parenteral nutrition, does not bring benefits, and may 
even be harmful to a patient. Such cases include:
 — PN for patients with a correct body mass and a correctly 
functioning gastrointestinal tract;
 — PN due to hypoalbuminemia, in patients where feeding 
by the gastrointestinal tract is possible (orally or ente-
rally);
 — Lack of refeeding syndrome prevention for cachectic 
patients starting PN or EN;
 — Use of feeding mixtures containing only soya oil as the 
sole fatty nutrient;
 — Incomplete nutrition (macronutrients or micronutrients 
only);
 — Classification of patients in the termination phase of 
cancer for PN undergoing persistent nutrition therapy.
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